Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

rivopharm sa - ropinirolum - compresse rivestite con film - ropinirolum 0.5 mg ut ropiniroli hydrochloridum, cellulosum microcristallinum, lactosum monohydricum 108.837 mg, carmellosum natricum conexum corresp. natrium max. 0.466 mg, magnesii stearas, coperta: hypromellosum, macrogolum 400, e 132, e 171, e 172 (flavum), e 172 (rubrum) pro compresso obducto. - morbo di parkinson - synthetika

Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

rivopharm sa - ropinirolum - compresse rivestite con film - ropinirolum 1 mg ut ropiniroli hydrochloridum, cellulosum microcristallinum, lactosum monohydricum 108.422 mg, carmellosum natricum conexum corresp. natrium max. 0.464 mg, magnesii stearas, coperta: hypromellosum, macrogolum 400, e 132, e 171, e 172 (flavum) pro compresso obducto. - morbo di parkinson - synthetika

Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

rivopharm sa - ropinirolum - compresse rivestite con film - ropinirolum 2 mg ut ropiniroli hydrochloridum, cellulosum microcristallinum, lactosum monohydricum 107.592 mg, carmellosum natricum conexum corresp. natrium max. 0.461 mg, magnesii stearas, coperta: hypromellosum, macrogolum 400, e 171, e 172 (flavum), e 172 (rubrum) pro compresso obducto. - morbo di parkinson - synthetika

Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

rivopharm sa - ropinirolum - compresse rivestite con film - ropinirolum 5 mg ut ropiniroli hydrochloridum, cellulosum microcristallinum, lactosum monohydricum 105.1 mg, carmellosum natricum conexum corresp. natrium max. 0.45 mg, magnesii stearas, coperta: hypromellosum, macrogolum 400, e 132, e 171 pro compresso obducto. - morbo di parkinson - synthetika

Unia Europejska - włoski - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformina cloridrato - diabete mellito, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Unia Europejska - włoski - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformina cloridrato - diabete mellito, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 e 5. 1 per i dati disponibili su diverse combinazioni).

Unia Europejska - włoski - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformina cloridrato - diabete mellito, tipo 2 - farmaci usati nel diabete - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Unia Europejska - włoski - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - ipertensione - agenti che agiscono sul sistema renina-angiotensina - trattamento dell'ipertensione essenziale.

Unia Europejska - włoski - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - ipertensione - agenti che agiscono sul sistema renina-angiotensina - trattamento dell'ipertensione essenziale.

Unia Europejska - włoski - EMA (European Medicines Agency)

novartis europharm ltd. - amlodipina, valsartan, idroclorotiazide - ipertensione - antagonisti dell'angiotensina ii, pianura, antagonisti dell'angiotensina ii, combinazioni di - trattamento dell'ipertensione essenziale come terapia sostitutiva in pazienti adulti in cui la pressione arteriosa è adeguatamente controllata la combinazione di amlodipina, valsartan e idroclorotiazide (hct), presa come tre formulazioni di singolo-componente o come un una formulazione monocomponente e bicomponente.